Similar articles for PMID: 21378350

Year	Number of Results
1967	1
1975	1
1978	2
1980	1
1982	1
1983	1
1991	3
1992	1
1993	2
1996	1
1998	1
1999	1
2000	1
2001	1
2002	2
2003	5
2004	4
2005	2
2006	5
2007	2
2008	5
2009	6
2010	5
2011	3
2012	4
2013	3
2014	5
2015	3
2016	2
2017	7
2018	12
2019	4
2020	3
2022	0

1

Prediction of response in cancer immunotherapy.

Characiejus D, Jacobs JJ, Pašukonienė V, Kazlauskaitė N, Danilevičiūtė V, Mauricas M, Den Otter W. Characiejus D, et al. Anticancer Res. 2011 Feb;31(2):639-47. Anticancer Res. 2011. PMID: 21378350 Review.

2

Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.

Lumsden AJ, Codde JP, Van der Meide PH, Gray BN. Lumsden AJ, et al. Anticancer Res. 1996 May-Jun;16(3A):1145-54. Anticancer Res. 1996. PMID: 8702226

3

[Research progress of gammadelta T cell-based immunotherapy].

Qiu FM, Li ZP, Huang J. Qiu FM, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 Jul;39(4):424-9. doi: 10.3785/j.issn.1008-9292.2010.04.016. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010. PMID: 20731045 Review. Chinese.

4

Cellular immunotherapy with dendritic cells in cancer: current status.

Nencioni A, Brossart P. Nencioni A, et al. Stem Cells. 2004;22(4):501-13. doi: 10.1634/stemcells.22-4-501. Stem Cells. 2004. PMID: 15277696 Free article. Review.

5

Imaging the immune response to monitor tumor immunotherapy.

Wang Q, Ornstein M, Kaufman HL. Wang Q, et al. Expert Rev Vaccines. 2009 Oct;8(10):1427-37. doi: 10.1586/erv.09.100. Expert Rev Vaccines. 2009. PMID: 19803763 Review.

6

Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?

Lissoni P, Brivio F, Viviani S, Fumagalli L. Lissoni P, et al. J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):110-4. J Biol Regul Homeost Agents. 1999. PMID: 10503734 Review.

7

[Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].

Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH, Tartour E. Benchetrit F, et al. Bull Cancer. 2003 Aug-Sep;90(8-9):677-85. Bull Cancer. 2003. PMID: 14609756 Free article. Review. French.

8

Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.

Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y, Li X, Bai C. Sun Z, et al. Clin Immunol. 2011 Jan;138(1):23-32. doi: 10.1016/j.clim.2010.08.012. Epub 2010 Oct 30. Clin Immunol. 2011. PMID: 21041120 Clinical Trial.

9

[The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].

Toh U, Fujii T, Tayama K, Yanaga H, Yokoyama G, Yamaguchi M, Horiuchi H, Sasatomi T, Takamori S, Shirouzu K, Seki N, Yamana H. Toh U, et al. Gan To Kagaku Ryoho. 2004 Oct;31(11):1649-51. Gan To Kagaku Ryoho. 2004. PMID: 15553672 Clinical Trial. Japanese.

10

Genetic redirection of T cells for cancer therapy.

Westwood JA, Kershaw MH. Westwood JA, et al. J Leukoc Biol. 2010 May;87(5):791-803. doi: 10.1189/jlb.1209824. Epub 2010 Feb 23. J Leukoc Biol. 2010. PMID: 20179152 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed